Gilead’s Yeztugo, a long-acting HIV capsid inhibitor, shows 96 to 100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support programs.
Jared Baeten, MD, PhD
Advertisement
Senior Vice President, Clinical Development, Virology Therapeutic Area Head at Gilead Sciences.
Articles by Jared Baeten, MD, PhD
The combination of the antiviral agents islatravir and lenacapavir demonstrates both efficacy and safety, leading to advancement into Phase 3 trials.
GS-1720 could offer a weekly dosing option for individuals living with HIV, supported by a good safety profile with no serious adverse events, which has led to the initiation of a Phase 2 study.
The Gilead capsid inhibitor has been shown to have less adverse events compared to another PrEP, and the company plans to begin regulatory filings for approval before the end of this year.
Advertisement
Latest Updated Articles
Further Data Finds Lenacapavir to Be Safe and Tolerable for PrEP UsePublished: October 15th 2024 | Updated: October 15th 2024
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV PreventionPublished: June 18th 2025 | Updated:
- Gilead's Phase 1a Trial Results Indicate GS-1720 as a Potential Long-Acting HIV Treatment
Published: October 16th 2024 | Updated:
Gilead and Merck Report Successful Phase 2 Results for Investigational Once-Weekly HIV TreatmentPublished: November 11th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Is 4 Weeks of Glecaprevir/Pibrentasvir Sufficient to Treat Early Hepatitis C Infection?
2
Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients
3
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
4
As NDM-CRE Infections Rise Significantly, Diagnostic Access Emerges as Weak Link
5
